ARQL News and Press, ArQule Inc. From 03/21/19

The following slide deck was published by ArQule, Inc. in conjunction with this Read more ...

ArQule, Inc. (Nasdaq: ARQL) today announced that Robert Weiskopf, Senior Vice President, Chief Financial Officer and Treasurer, has decided to retire effective March 29 of this year. In conjunction with Mr. Weiskopf’s departure, ArQule is naming Marc Schegerin, MD as Chief Financial O...

ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Brian Schwartz, MD, Chief Medical Officer and Head of Research and Development, of ArQule will present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 at 10...

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in the 31st Annual ROTH Conference on March 17-19, 2019 in Dana Point, California. About ArQ...

ArQule, Inc. (ARQL) Q4 2018 Earnings Conference Call March 07, 2019, 09:00 AM ET Company Participants Marc Schegerin - SVP of Strategy, Finance and Communications Paolo Pucci - CEO Brian Schwartz - Head of R&D Rob Weiskopf - CFO Conference Call Participants Jonathan C...

Gainers:  Bio-Path Holdings (NASDAQ: BPTH ) +201% . Seelos Therapeutics (NASDAQ: SEEL ) +79% . ArQule (NASDAQ: ARQL ) +66% . Altimmune (NASDAQ: ALT ) +60% . Rosetta Stone (NYSE: RST ) +31% . Calumet Specialty Products Partners (NASDAQ: CLMT ) +29% . Cleveland BioLabs (NASDAQ: CB...

ArQule ( ARQL +48.6% ) is up on more than double normal volume in early trade following its Q4 repor t that featured a revenue beat, albeit by only $1.1M, from its licensing deal with Sinovant. More news on: ArQule, Inc., Healthcare stocks news, Stocks on the move, Read more ...

ArQule (NASDAQ: ARQL ): Q4 GAAP EPS of -$0.08 misses by $0.01 . More news on: ArQule, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Conference call scheduled today at 9:00 a.m. ET ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the fourth quarter and full year of 2018. For the quarter ended December 31, 2018, the Company reported a net loss of $8,487,000 or $0.08 per share, compared wit...

ArQule ( ARQL +3.3% ) is up on below-average volume in response to preliminary data on miransertib in patients with Proteus syndrome, an ultra-rare condition characterized by abnormal overgrowth of multiple tissue which changes the shape of body structures over time.The results were just...